In life sciences, translation isn’t a language task. It’s a regulatory task that happens to involve languages.
That distinction matters because it shapes everything about how life sciences documentation translation should be approached. The regulatory frameworks governing pharmaceuticals, medical devices, and biotechnology products don’t treat translation as an afterthought. They treat it as part of the compliance architecture. Documentation that doesn’t meet language requirements isn’t just inconvenient – it’s non-compliant.
For companies entering or operating in life sciences sectors, understanding what makes this documentation different is the first step to managing it properly.
The regulatory context shapes everything
Life sciences documentation exists within regulatory frameworks that are unusually prescriptive about language. The European Medicines Agency, the UK’s MHRA, and national competent authorities across Europe all have specific requirements about which documents must be translated, into which languages, and to what standards.
This isn’t discretionary. A marketing authorisation application submitted to EMA requires documentation in English. Product information – the Summary of Product Characteristics, package leaflet, and labelling – must be provided in all official EU languages for centrally authorised products. National procedures have their own language requirements. The MHRA has its own expectations post-Brexit.
Medical device regulation operates similarly. Under the EU MDR, instructions for use must be provided in the official language(s) of the Member State where the device is made available. Labels must include required information in those languages. Clinical evaluation reports, technical documentation, and declarations of conformity all have language implications depending on where you’re placing products on the market.
These requirements aren’t negotiable, and regulators actively check compliance. Language deficiencies in submitted documentation can delay approvals. Language deficiencies in marketed products can trigger enforcement action. The regulatory stakes make translation quality a compliance issue, not just a communication preference.
Clinical documentation requires specific expertise
Clinical documentation translation presents challenges that go beyond general medical or scientific translation.
Clinical trial documentation – protocols, informed consent forms, patient-facing materials – must be translated with extreme precision. Informed consent documents are both legal and ethical instruments. Patients make decisions about trial participation based on these documents. Errors or ambiguities don’t just create confusion; they potentially compromise the ethical basis of the trial.
Clinical study reports and regulatory submissions require translators who understand both the science and the regulatory context. These documents follow specific structures and conventions. They use terminology that has precise regulatory meaning. A translator working on a clinical study report needs to understand not just the language but the regulatory framework the document exists within.
Pharmacovigilance documentation – adverse event reports, periodic safety update reports, risk management plans – operates under strict timelines and formats. Translations must be accurate and timely, with no room for delays that could affect safety reporting obligations.
The common thread is that clinical documentation translation requires specialists who work in this domain regularly. General medical translators may have the scientific vocabulary but lack the regulatory context. General technical translators may understand compliance frameworks but lack the clinical expertise. Life sciences documentation needs both.
Terminology standards add complexity
Life sciences uses controlled terminology in ways that most industries don’t. MedDRA (Medical Dictionary for Regulatory Activities) provides standardised terminology for adverse event reporting. WHO-DD provides standardised drug dictionaries. ICH guidelines establish conventions for clinical documentation.
Translators working with life sciences documentation need to work within these terminological frameworks, not around them. Using non-standard terms, even if technically accurate, can create problems in regulatory submissions and pharmacovigilance databases. The translation must use the approved terminology in the target language, which means translators need access to and familiarity with these resources.
Terminology management becomes critical at scale. A pharmaceutical company with products across multiple therapeutic areas, documented in multiple languages, needs systematic terminology governance. Ad hoc translation without centralised terminology creates inconsistencies that accumulate over time – different translations of the same term in different documents, conflicts between labels and package leaflets, discrepancies between submitted and marketed documentation.
Quality systems and audit trails matter
Life sciences companies operate under quality management systems that extend to documentation – including translated documentation. Good Manufacturing Practice, Good Clinical Practice, and Good Documentation Practice all have implications for how translations are managed.
Audit trails for translated documents need to demonstrate who translated what, when, and through what review process. Regulators examining a quality system want to see that translation is controlled, not ad hoc. They want evidence that translations are reviewed by qualified personnel, that changes are tracked, and that versions are controlled.
Validation of translation processes may be required depending on the documentation type and regulatory context. For patient-facing materials, back-translation and reconciliation processes are common. For labelling, additional verification steps ensure that what appears on the product matches what was approved.
Document control must encompass translated versions as thoroughly as source documents. When a source document is updated, the translated versions need updating through a controlled process. When a translation is approved, it needs to be locked against unauthorised changes. Version control needs to track translated documents alongside their source documents.
This quality infrastructure adds cost and complexity to life sciences translation. But it’s not optional – it’s part of operating in a regulated environment.
Labelling and packaging present specific challenges
Product labelling and packaging translation in life sciences combines regulatory precision with practical constraints that don’t apply to other documentation.
Space constraints are severe. A medicine package has limited real estate, and that space must accommodate required information in multiple languages. Text expansion from English – particularly significant for some European languages – creates layout challenges. Information that must appear by regulation cannot be abbreviated or reformatted to fit.
Regulatory requirements specify exactly what must appear on labels and in what form. Warning statements, dosage instructions, storage conditions, and expiry information all have required formats. Translations must preserve these requirements exactly while working within physical space limitations.
Multilingual packaging for products sold across multiple markets requires coordination between translation, regulatory affairs, and packaging design. Changes to any element – text, design, or regulatory requirement – ripple through the entire multilingual package. Managing these changes without introducing errors requires systematic processes and careful quality control.
The consequences of labelling errors are immediate and serious. A mislabelled medicine is a patient safety issue. Regulatory authorities take labelling non-compliance seriously, and recalls for labelling errors are not uncommon in the industry.
What this means for translation partnerships
Life sciences documentation translation isn’t a commodity service. The regulatory context, terminology requirements, and quality expectations mean that choosing translation partners based primarily on price is a false economy.
Expertise verification matters. Translators working on life sciences documentation should have demonstrable experience in the therapeutic or product areas involved. They should understand the regulatory frameworks governing the documentation. They should be familiar with the terminology standards and controlled vocabularies used in the industry.
Quality systems at the translation provider should align with life sciences expectations. ISO 17100 certification for translation services is a baseline. Experience working with life sciences clients under their quality systems demonstrates capability to operate in regulated environments.
Confidentiality and data protection take on additional importance given the sensitive nature of clinical and patient data that may appear in documentation. Translation partners need appropriate agreements, systems, and practices for handling confidential information.
Responsiveness and reliability matter because life sciences timelines are often driven by regulatory deadlines that cannot slip. A marketing authorisation submission date, a clinical trial start date, or a pharmacovigilance reporting deadline creates hard constraints on when translated documentation must be ready.
At Bubbles, we work with life sciences companies across pharmaceuticals, medical devices, and biotechnology. We understand that translation in this sector is a regulatory function, not just a language service – and we bring the expertise, quality systems, and reliability that regulated environments demand.
